Aurinia Pharmaceuticals Inc.

AUPH

$16.11

-0.09%

2026-09-04 10:33:16 EDT-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is ...

Price Action of AUPH

$16.11

-0.09%-$0.01

High—

Low—

52W High-16.3%

Rel. vol—

Interval

Range63m

Volume—SMA5SMA10

—

Aurinia Pharmaceuticals Inc. (AUPH) is a commercial-stage biopharmaceutical company developing and delivering innovative treatments for patients with autoimmune diseases. The company’s mission centers on addressing conditions where existing medical solutions are inadequate, with a particular emphasis on lupus nephritis—a serious complication of lupus that can lead to significant morbidity. The ...Aurinia Pharmaceuticals Inc. (AUPH) is a commercial-stage biopharmaceutical company developing and delivering innovative treatments for patients with autoimmune diseases. The company’s mission centers on addressing conditions where existing medical solutions are inadequate, with a particular emphasis on lupus nephritis—a serious complication of lupus that can lead to significant morbidity. The company’s flagship product is LUPKYNIS (voclosporin), an FDA-approved oral therapy for adult patients with active lupus nephritis. As a commercial product, LUPKYNIS places Aurinia in the category of revenue-generating biopharma operations, where the business is driven by ongoing manufacturing and supply, payer/provider contracting, marketing and sales execution, and post-approval clinical and pharmacovigilance activities. The company also maintains strategic collaboration and licensing arrangements, including an agreement with Otsuka Pharmaceutical Co., Ltd., which reflects a common industry model for sharing development, commercialization, and market-expansion capabilities. From a products and services perspective, Aurinia’s core “service” is therapeutic development and commercialization: identifying patient populations, supporting clinical evidence generation, navigating regulatory pathways, and then executing commercial commercialization for approved therapies. Typical cost drivers for companies in Aurinia’s position include R&D (continued clinical development and life-cycle management), manufacturing and quality systems (for small-molecule oral drugs), commercialization expenses (sales force and marketing), and corporate functions such as regulatory, medical affairs, and pharmacovigilance. Financially, companies like Aurinia are often evaluated on operating performance, product revenue trajectory, cash generation, and the ability to fund ongoing development and business needs without excessive dilution. While specific segment financial breakdowns are not provided in the supplied data, the company’s valuation metrics and profitability indicators in the dataset reflect an actively trading, product-focused business with meaningful margins and strong liquidity indicators typical of biopharma firms that have reached commercialization. Key leadership includes Kevin C. Tang, who serves as Chair of the Board and Chief Executive Officer. The company is headquartered in Edmonton, Alberta, Canada, and serves patient populations in the United States and internationally. Overall, Aurinia’s near-term “wish list” (based on typical priorities for a commercial-stage biopharmaceutical company) would likely include sustaining LUPKYNIS demand, expanding evidence and appropriate-use positioning through continued clinical and real-world data, and leveraging partnerships to broaden geographic reach and development pipeline momentum.ExpandCollapse

Founded

2012

Employees

128

CEO

Kevin C. Tang

Full Name

Aurinia Pharmaceuticals Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

59.00%

Market Cap

$2.14B

Current Ratio

5.42

WACC

10.96%

ROIC

64.42%

Contact Information

https://www.auriniapharma.com

12507084272

#140, 14315 – 118 Avenue, Edmonton, AB T5L 4S6

Key Metrics of AUPH

Snapshot

Latest / TTM · 6 periods

Market Cap

$2.14B

ROCE

21.8%

EV / EBITDA

10.38x

+5.8% YoY

FCF Yield

8.4%

+2.1% YoY

Cash Conversion Cycle

575.8d

Current Ratio

5.42

Quick take

TTM —

Positive CCC

Financial Highlights of AUPH

Profitability trend

Latest / TTM · 6 periods

Gross Margin

90.4%

Net Margin

100.8%

P/E Ratio

6.83x

n/a

Debt / Equity

0.10

n/a

Current Ratio

5.42

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of AUPH

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.22 · Revenue $83.61M · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.20 · Revenue $85.71M · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.94 · Revenue $330.27M · 4 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.17 · Revenue $80.90M · 1 analysts

Recent history

Aug 6, 2026
Q2 FY2026 · Results reported
EPS $0.28 · Revenue $83.22M
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $0.25 · Revenue $77.70M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $2.07 · Revenue $283.06M
View filing
Nov 4, 2025
Q3 FY2025 · Results reported
EPS $0.23 · Revenue $73.47M
View filing
Jul 31, 2025
Q2 FY2025 · Results reported
EPS $0.15 · Revenue $70.01M
View filing
May 12, 2025
Q1 FY2025 · Results reported
EPS $0.16 · Revenue $62.47M
View filing

Financial Statements of AUPH

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$283.1M	+20.4%	+7.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$287.2M	+4893.1%	+8.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+88.5%	+0.5%	+0.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+37.1%	+1959.4%	+4.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+101.5%	+4047.7%	+1.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$135.4M	+207.0%	+60.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+47.8%	+155.0%	+49.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	12.9%	-38.8%	-18.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	5.25x	+14.9%	-2.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$751.6M	+36.5%	+9.4%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	2.07 vs 0.78	+164.8%	0.28 vs 0.24	+16.7%
Revenue Surprise	$283.1M vs $280.6M	+0.9%	$83.2M vs $80.4M	+3.4%

Insider Transactions of AUPH

Acquisitions (A)

Since May 29, 2026

Disposals (D)

Since May 29, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 21, 2026	Robertson Stephen P.	officer: Chief Legal Officer	Common Stock	D	20,975	$16.97
Jun 4, 2026	Johnson Craig A	director	Director Stock Option (right to buy)	A	23,931	$15.67
Jun 4, 2026	Goetz Kathleen	director	Director Stock Option (right to buy)	A	23,931	$15.67
Jun 4, 2026	Nova Tina Susan	director	Director Stock Option (right to buy)	A	23,931	$15.67
Jun 4, 2026	Bailey Jeffrey Allen	director	Director Stock Option (right to buy)	A	23,931	$15.67

Earnings Call Transcript of AUPH

1 transcript segments

Q4 2025

Unknown Speaker

Operator: Good morning. Welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full Year 2025 Conference Call. Please be advised that a Q&A session will follow Aurinia prepared remarks. [Operator Instructions]. I will now turn the call over to Peter Greenleaf, President and Chief Executive Officer of Aurinia. Peter, please go ahead. Peter Greenleaf: Good morning. We want to thank you all for joining us today to discuss Aurinia's Fourth Quarter and Full Year 2025 Update. Joining me on the call today are Joe Miller, our Chief Financial Officer; and Dr. Greg Keenan, our Chief Medical Officer. On today's call, we will report fourth quarter and full year 2025 financial results and provide an update on recent business progress. During today's call, we may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. We are pleased to have delivered strong LUPKYNIS sales in 2025, growing at a rate of 25% year-over-year. And for 2026, we expect net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. And with that introduction, I'd like to now turn the call over to Joe to review our financial results. Joe? Joseph Miller: Thank you, Peter. Total revenue for the fourth quarter of 2025 was $77.1 million, up 29% compared to $59.9 million for the same period of 2024. Net product sales of LUPKYNIS for the fourth quarter of 2025 were $74.2 million, up 29% compared to $57.6 million in 2024. Net income for the fourth quarter of 2025 was $210.8 million, up 14,957% from $1.4 million in 2024. In the fourth quarter of 2025, the company recorded an income tax benefit of $175.1 million, primarily due to the release of its valuation allowance on deferred tax assets that the company now expects to realize. Net income before income taxes for the fourth quarter of 2025 was $35.7 million, up 2,875% from $1.2 million in 2024. Diluted earnings per share for the fourth quarter of 2025 was $1.53, up 15,200% from $0.01 in 2024. Lastly, cash flows from operating activities for the fourth quarter of 2025 were $45.7 million, up 52% from $30.1 million in 2024. Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% compared to the $235.1 million for the same period of 2024. As a reminder, the 2024 period included a milestone payment of $10 million associated with LUPKYNIS regulatory approval in Japan. Excluding the onetime milestone, total revenue increased by 26% over the same period in 2024. Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024. Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024. For the year ended December 31, 2025, the company recorded an income tax benefit of $173 million, primarily due to the release of its valuation allowance on deferred tax assets …

Leadership Team of AUPH

7 executives

Name	Title	Compensation	Gender	Year Born	Status
Peter S. Greenleaf	Consultant	USD 1,700,080	Male	1970	Active
Stephen Robertson	Chief Legal Officer, Corporate Secretary & Chief Compliance Officer	USD 923,480	Male	1982	Active
Michael S. Hearne	Chief Financial Officer	USD 866,870	Male	1963	Active
Stewart Kroll	Chief Development Officer	—	Male	1959	Active
Thomas Wei	Chief Scientific Officer	—	Male	1976	Active
Kevin C. Tang	Chairman & CEO	—	Male	1967	Active
Ryan Cole	Chief Operating Officer	—	Male	1987	Active

Recent News of AUPH

Zacks Investment Research8/20/2026Neutral

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Benzinga8/20/2026Neutral

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Business Wire8/19/2026Neutral

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Seeking Alpha8/12/2026Neutral

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.

Zacks Investment Research8/6/2026Neutral

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.

Historical Employee Count of AUPH

Current

128

Change

-1.54%

Minimum

128

Maximum

300

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	128	10-K	Feb 26, 2026	View
Dec 31, 2024	130	10-K	Feb 27, 2025	View
Dec 31, 2023	300	10-K	Feb 15, 2024	View
Dec 31, 2022	300	10-K	Feb 28, 2023	View
Dec 31, 2021	300	10-K	Feb 28, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Aurinia Pharmaceuticals Inc.